Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Mar;7(1):20-27.
doi: 10.1159/000486487. Epub 2018 Jan 31.

Combination Cancer Immunotherapy in Hepatocellular Carcinoma

Masatoshi Kudo  1
Affiliations
Editorial

Combination Cancer Immunotherapy in Hepatocellular Carcinoma

Masatoshi Kudo. Liver Cancer. 2018 Mar.
No abstract available

PubMed Disclaimer

Figures

None
Prof. M. Kudo Editor Liver Cancer
Fig. 1
Fig. 1
Treatment strategy using immune checkpoint inhibitors. Future direction: combination therapy. RFA, radiofrequency ablation; TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; TKIs, tyrosine kinase inhibitors.
Fig. 2
Fig. 2
Mechanism of synergistic effects of lenvatinib and anti-PD-1/PD-L1 antibodies. a Immunosuppressive microenvironment + PD-1/PD-L1 immunosuppression. b Lenvatinib + anti-PD-1/PD-L1 antibodies synergistically induce PD-1/PD-L1 blockade and inhibit the immunosuppressive microenvironment.
Fig. 3
Fig. 3
Phase Ib study of lenvatinib plus pembrolizumab in hepatocellular carcinoma.
Fig. 4
Fig. 4
Adjuvant treatment with anti-PD-1 antibody to prevent recurrence after curative treatment of HCC. HCC, hepatocellular carcinoma; RFA, radiofrequency ablation; ECOG PS, Eastern Cooperative Oncology Group Performance Status; IC, informed consent.
Fig. 5
Fig. 5
Improved overall survival as a result of combination therapy: very near future. MST, median survival time.
See this image and copyright information in PMC

References

    1. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133. - PMC - PubMed
    1. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311–319. - PMC - PubMed
    1. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532. - PubMed
    1. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–2028. - PubMed
    1. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135. - PMC - PubMed

Publication types